lenvatinib and Cystadenocarcinoma--Serous

Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Female; Humans; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Suppressor Protein p53; Uterine Neoplasms